Exosome Strain Screening & Identification
OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs
Overview
At Creative BioMart Microbe, we operate a dedicated platform for the systematic screening, identification, and qualification of microbial extracellular vesicle (EV)-producing strains. Our service spans the full continuum from raw strain library evaluation through high-yield producer selection, genetic stability verification, endotoxin safety engineering, and fermentation pre-adaptability assessment. We work with Gram-negative bacteria (OMV producers), Gram-positive bacteria (GP-EV / CMV producers), GRAS/QPS probiotic isolates, and yeast / fungal species to identify and engineer host organisms that secrete EVs with optimal yield, consistent physicochemical profiles, and application-appropriate safety attributes.
Unlike generic contract research organizations that apply mammalian cell-derived exosome protocols to microbial systems, our screening assays, yield quantification methods, and strain qualification criteria are purpose-built for bacterial outer membrane vesicles (OMVs), probiotic-derived exosomes, and fungal EVs. Every strain entering our pipeline is evaluated against a species-specific critical quality attribute (CQA) baseline that we establish through in-house reference databases. Clients receive a complete strain dossier that supports downstream fermentation optimization, isolation and purification, and regulatory filing strategies.
Strain screening establishes the manufacturing foundation for any microbial EV program. Our platform maintains technical continuity from initial producer identification through Exosome-Producing Strain Engineering & Fermentation Optimization, Exosome Isolation & Purification, and Exosome Functional Validation & Mechanism of Action Studies, with strain-specific CQA baselines informing every subsequent phase. This integrated approach eliminates data loss and rework when transitioning between development stages. Contact us for a custom project consultation.
Figure 1. Schematic overview of the integrated exosome strain screening and identification platform, spanning strain library evaluation, high-yield producer ranking, genetic stability assessment, endotoxin safety engineering, and fermentation pre-adaptability qualification.
Services
Service Workflow
Service Details
Strain Library Screening & High-Yield Producer Identification
We maintain and evaluate diverse microbial strain repositories encompassing Gram-negative bacteria, Gram-positive bacteria, GRAS/QPS probiotic isolates, and yeast species. Primary screening employs nanoparticle tracking analysis (NTA), flow cytometry, and total protein quantification to rank strains by EV secretion capacity. High-yield candidates advance to secondary confirmation with batch-to-batch consistency testing across three independent fermentation runs to eliminate false positives from single-batch outliers.
Genetic Stability & Passage Integrity Assessment
We monitor genomic sequence consistency, plasmid retention rates, and EV yield decay across serial passages to ensure producer strains remain genetically stable throughout manufacturing campaigns. Strains qualified for clinical or commercial applications undergo master cell bank (MCB) and working cell bank (WCB) characterization with documented genetic stability over defined passage limits.
Endotoxin Safety Engineering & Strain Qualification
We classify strains by baseline lipopolysaccharide (LPS) or lipoteichoic acid (LTA) profiles and apply genetic engineering strategies—including msbB knockout and LPS structural modification—to lower the inflammatory potential of OMV preparations for in vivo and therapeutic applications. GRAS/QPS status is verified for food-grade and cosmetic-grade strains, and comprehensive host safety dossiers are prepared to support regulatory submissions.
Engineered Strain Development for Enhanced EV Secretion
Using synthetic biology and CRISPR-based genome editing, we construct hypervesiculating mutants, overexpress vesicle secretion pathway genes, and integrate surface-display scaffold proteins for downstream targeting engineering. Reporter genes and fluorescent markers can be introduced to enable real-time secretion monitoring and purification tracking.
Strain-Specific Characterization & Quality Profiling
Each qualified strain is profiled for EV size distribution, zeta potential, total protein/lipid/nucleic acid yield, key membrane protein fingerprints, and LPS/LTA signatures. These data establish a strain-specific CQA baseline that informs downstream process development and lot-release specifications.
Fermentation Pre-Adaptability & Scalability Assessment
We conduct small-scale fermentation pre-studies to evaluate media compatibility, pH and dissolved oxygen operating windows, and yield-to-OD correlation curves. Strains demonstrating robust scalability receive a fermentation transition report that enables seamless handoff to our Exosome-Producing Strain Engineering & Fermentation Optimization service.
Service Specifications & QC Standards
Screening & Identification Capability
- Multi-species coverage: Gram-negative bacteria, Gram-positive bacteria, probiotic strains, and yeast.
- Screening dimensions: EV yield, particle size consistency, zeta potential stability, endotoxin profile, and genetic stability.
- Engineering tools: CRISPR-Cas9, transposon mutagenesis, plasmid-based overexpression, and synthetic secretion pathway design.
- Analytical stack: NTA, DLS, cryo-TEM, flow cytometry, Western blot, mass spectrometry, and endotoxin assays.
- Safety modules: msbB knockout, LPS structural modification, and GRAS/QPS verification.
- Assay design aligned with MISEV2023 guidelines; GxP-compliant formats available for regulatory submissions.
Typical Data Range
- High-yield strain EV titer improvement: 3–60× over baseline wild-type.
- Endotoxin level for engineered strains: ≤0.5 EU/mL for preclinical in vivo use, ≤0.1 EU/mL for IND-enabling / low-endotoxin programs
- Genetic stability passage limit: >30 passages with <10% yield decay.
- EV particle size consistency across batches: CV <15%.
- Zeta potential range: −30 to −50 mV for Gram-negative OMVs; −20 to −40 mV for probiotic EVs.
- Surface ligand density (engineered display strains): 102–104 molecules per vesicle.
- Batch-to-batch EV yield CV: <15%.
Turnaround Time
| Project Type |
Timeline |
| Primary strain library screening and ranking |
2–3 weeks |
| High-yield producer confirmation (3-batch) |
3–4 weeks |
| Genetic stability assessment |
2–4 weeks |
| Endotoxin safety engineering and qualification |
3–5 weeks |
| Engineered strain development (hypervesiculation or display) |
4–6 weeks |
| Strain-specific characterization and CQA baseline |
2–3 weeks |
| Fermentation pre-adaptability assessment |
2–3 weeks |
| MCB/WCB establishment and documentation |
3–4 weeks |
| Complete screening-to-qualification project |
10–14 weeks |
Timeline may vary based on strain complexity, engineering scope, and assay customization. Stages may run in parallel where feasible (e.g., genetic stability assessment can overlap with engineered strain development and fermentation pre-adaptability testing). Sequential execution may extend the overall timeline to 18–24 weeks.
Deliverables
- Experimental protocols and SOP summaries.
- Raw data files (NTA datasets, flow cytometry FCS files, sequencing data, MS raw data).
- Processed analytical reports with statistical analysis and publication-ready charts.
- Strain dossier including genetic background, EV profile, and safety qualification.
- Certificate of Analysis (CoA) per qualified strain batch.
- Master and working cell bank documentation (if applicable).
- Fermentation pre-adaptability transition report.
- Optional CQA documentation package for IND-enabling studies.
Quality Control
- Batch-level instrument calibration with certified positive and negative controls.
- Inter-batch consistency assessment (EV yield CV <15%, size CV <15%).
- MISEV2023 compliance checklist for all screening and characterization assays.
- Endotoxin monitoring for all in vivo-grade strains.
- Genetic stability verification by sequencing and plasmid retention assay.
- Sterility and contaminant screening for all cell bank materials.
- Optional GxP-aligned assay validation and CQA trending analysis for lot-release documentation.
Sample Requirements
| Sample Category |
Required Information |
Recommended Quantity |
Acceptance Criteria |
Not Accepted |
| Raw microbial strains |
Strain name/ID, species background, source documentation, culture conditions, target application |
2–3 glycerol stocks or agar stabs per strain |
Viable upon revival, documented passage history, sterile preparation |
Unidentified species, undocumented passage history, contaminated cultures |
| Fermentation supernatants |
Strain ID, fermentation media composition, harvest OD, culture volume |
≥500 mL per condition for primary screening; ≥2 L for high-yield confirmation |
Harvested at defined growth phase, filtered or centrifuged to remove cells, shipped cold |
Samples with undefined harvest point, severe cell contamination, detergent residues |
| Purified EV preparations |
Strain ID, isolation method, particle concentration, buffer composition |
≥200 μg total protein or ≥2×10⁹ particles per batch |
Purified via TFF, SEC, or ultracentrifugation; endotoxin level documented |
Samples with >3 freeze-thaw cycles, unidentified strain origin, fixative preservatives |
| Screening requirement documents |
Target EV application, desired yield target, safety grade (research/in vivo/food/cosmetic/GMP), engineering requests |
N/A (consultation-only submissions accepted) |
Clear project scope and deliverable expectations |
Vague or undefined project objectives |
Storage & Shipping: Ship glycerol stocks and live cultures on dry ice with cold-chain documentation. Purified EVs should be shipped frozen at −80°C on dry ice. Store at −80°C upon receipt. Avoid repeated thawing. Recommended buffer: sterile PBS, pH 7.4, endotoxin-free. Live engineered strains should be shipped on glycerol stocks or agar stabs with complete cold-chain documentation.
Our Advantages
- Microbial EV-Specific Screening Expertise: Deep specialization in Gram-negative bacterial OMVs, Gram-positive bacterial EVs, probiotic-derived EVs, and fungal EVs. Every screening assay and yield quantification method is optimized for microbial membrane composition and secretion mechanisms, not adapted from mammalian exosome templates.
- Multi-Species Strain Repository: Access to diverse Gram-negative, Gram-positive, probiotic, and yeast strain libraries enables rapid identification of optimal producers for therapeutic, vaccine, food-grade, or cosmetic applications.
- Synthetic Biology-Enabled Engineering: From hypervesiculating mutants to surface-display scaffold integration, we engineer strains for enhanced yield, reduced endotoxin, and downstream targeting compatibility within a single workflow.
- Safety-First Qualification: Endotoxin profiling and genetic engineering (msbB knockout, LPS modification) are conducted in parallel with yield screening, ensuring qualified strains meet in vivo and regulatory safety standards from the outset.
- Genetic Stability & Cell Banking: Rigorous passage monitoring and MCB/WCB establishment with full documentation support long-term manufacturing consistency and GMP compliance.
- Strain-to-Fermentation Continuum: Fermentation pre-adaptability assessments deliver media compatibility, pH/DO operating windows, and yield-OD correlation data that enable seamless transition to process development and scale-up.
Applications
Vaccine Development & OMV-Based Adjuvants
High-yield OMV-producing strains are screened and engineered for optimal adjuvant potency and antigen display capacity. Endotoxin-reduced variants support safe immunization profiles in next-generation bacterial and viral vaccine platforms.
Targeted Drug Delivery & Therapeutic BEVs
Engineered bacterial EV producer strains are developed for low-endotoxin, high-yield therapeutic vesicle manufacturing. Strain qualification ensures consistent targeting ligand display and cargo loading compatibility for oncology, immunology, and infectious disease applications.
Probiotic & Functional Food-Grade EVs
GRAS/QPS probiotic strains are screened for EV secretion capacity, GI stability, and bioactive cargo profiles. Qualified strains support functional food, nutraceutical, and dietary supplement development with documented safety and compliance dossiers.
Cosmetic & Skin-Barrier Repair EV Sources
Microbial strains are evaluated for skin-repair bioactivity and cosmetic raw-material compliance. High-activity producers are qualified for downstream formulation in skincare, dermatological, and regenerative cosmetic applications.
Case Study
Case Study 1: Rapid Screening of Bacterial EMV Production Genes via Curvature-Sensing Peptide
Researchers developed a high-throughput screening platform using the curvature-sensing peptide nFAAV5-NBD to identify genes governing bacterial extracellular membrane vesicle (EMV) production in Shewanella vesiculosa HM13. Unlike conventional methods requiring cell-EMV separation, nFAAV5-NBD selectively binds lipid packing defects on EMV membranes, enabling in situ fluorescence-based quantification directly in culture. From a library of ~10,000 random transposon mutants, the screen identified 16 hyper-vesiculating and 6 hypo-vesiculating mutants with transposon insertions within or near defined genes. Subsequent gene mapping and targeted disruption validated eight genes that increase EMV yield—including dipeptidyl carboxypeptidase, LapG protease, and RNA polymerase sigma-54 factor—and four genes that decrease production, such as phosphoenolpyruvate synthase and glutamate synthase. The study reveals that protein quality control, environmental signal sensing, and glutamate metabolism collectively regulate EMV biogenesis, and the hyper-vesiculating mutants represent valuable engineered hosts for high-yield vesicle manufacturing.
Figure 2. Rapid screening of bacterial EMV production mutants using curvature-sensing peptide nFAAV5-NBD. (Inoue, et al., 2025)
Case Study 2: Strain Selection and Cultivation Optimization for Enhanced Probiotic Membrane Vesicle Bioactivity
Researchers compared membrane vesicle (MV) production and functional profiles between Limosilactobacillus reuteri DSM 17938 and its selectively bred derivative BG-R46 to identify strain-specific and cultivation-dependent determinants of vesicle bioactivity. BG-R46, isolated through bile-stress selection, produced MV with 7-fold higher 5′-nucleotidase activity than DSM 17938 despite equivalent particle concentrations, and demonstrated superior epithelial barrier protection against ETEC challenge. Cultivation parameters significantly influenced MV yield and composition: oxygen stress and 48-hour cultivation increased particle concentrations and protein content compared to standard 24-hour conditions. Proteomic analysis revealed strain-conserved surface proteins involved in host adhesion and immunomodulation, while functional assays confirmed dose-dependent TRPV1 antagonism and cytokine modulation distinct from L. rhamnosus GG MV. These findings demonstrate that strategic strain selection combined with cultivation condition optimization can substantially enhance MV functional potency for probiotic and therapeutic applications.
Figure 3. Physicochemical characterization of L. reuteri derived MV through nanoparticle tracking analysis. (Pang, et al., 2022)
FAQs
Q: What types of microorganisms can be screened for EV production?
A: We screen Gram-negative bacteria (including OMV producers), Gram-positive bacteria, GRAS/QPS probiotic strains, and yeast species. Our assays are optimized for each microbial class to ensure accurate yield quantification and physicochemical characterization.
Q: How do you quantify and rank exosome secretion capacity across different strains?
A: Primary screening combines NTA for particle concentration, flow cytometry for vesicle-specific marker abundance, and total protein quantification. Strains are ranked by EV yield per optical density unit, and top candidates undergo three-batch confirmation to verify consistency.
Q: Can you engineer strains to enhance EV yield or reduce endotoxin levels?
A: Yes. We apply CRISPR-based genome editing and transposon mutagenesis to construct hypervesiculating mutants, overexpress secretion pathway genes, and modify LPS biosynthesis genes (msbB knockout) to reduce endotoxin while maintaining or enhancing yield.
Q: What is the difference between natural strain screening and engineered strain development?
A: Natural screening identifies high-yield wild-type strains from existing libraries. Engineered development introduces targeted genetic modifications—such as secretion pathway amplification or surface-display scaffold integration—to create bespoke producer strains for specific applications.
Q: How is genetic stability assessed during strain qualification?
A: We monitor genomic sequence consistency, plasmid retention rates, and EV yield across serial passages. Strains qualified for clinical or commercial use must demonstrate stable yield within defined acceptance criteria over the specified passage limit.
Q: Do you provide GMP-compliant master and working cell banks?
A: Yes. Qualified strains can be deposited as master cell banks (MCB) and working cell banks (WCB) with full characterization documentation, including genetic stability, sterility, and identity verification, prepared to support regulatory submissions.
Q: What strain-specific safety qualifications are required for in vivo or clinical applications?
A: In vivo-grade strains require endotoxin ≤0.5 EU/mL (preclinical) or ≤0.1 EU/mL (IND-enabling), plus documented sterility, complete genetic background annotation, and absence of adventitious agents. We prepare comprehensive safety dossiers aligned with IND-enabling and CMC package requirements.
Q: How does strain screening data integrate with downstream fermentation optimization?
A: Every qualified strain receives a fermentation pre-adaptability report detailing media compatibility, optimal pH and dissolved oxygen ranges, and yield-OD correlation data. This report enables seamless handoff to our fermentation optimization team for scale-up development.
References:
- Inoue, H., et al. (2025). Rapid screening and identification of genes involved in bacterial extracellular membrane vesicle production using a curvature-sensing peptide. Journal of Bacteriology, 207(5), e00497-24.
- Pang, Y., et al. (2022). Extracellular membrane vesicles from Limosilactobacillus reuteri strengthen the intestinal epithelial integrity, modulate cytokine responses and antagonize activation of TRPV1. Frontiers in Microbiology, 13, 1032202.
